Arrowhead Pharmaceuticals Inc

0 DAYS LEFT TO SEEK LEAD PLAINTIFF STATUS

Case Summary
Company Name: Arrowhead Pharmaceuticals Inc
Stock Symbol : NASDAQ: ARWR
Class Period Start: 05/11/2015
Class Period End: 11/08/2016
Lead Plaintiff motion: 01/16/2017
Date Filed: 11/15/2016
Type of Case: Securities Class Action
Court: U.S. District Court for the Central District of California
Summary:

Thieler Law Corp advises investors with losses exceeding $100,000 of the January 16, 2017 lead plaintiff deadline in a class action lawsuit filed against Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) (“Arrowhead” or “the Company”). The suit is pending in the U.S. District Court for the Central District of California and investors, who purchased Arrowhead Pharmaceuticals Inc securities between May 11, 2015 and November 8, 2016, have until January 16, 2017 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class.

If you purchased Arrowhead Pharmaceuticals Inc securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class.

The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that its drug candidate ARC-520 was fatal at certain doses; that the U.S. Food & Drug Administration was unlikely to approve ARC-520 as a hepatitis B treatment; that the Company overstated the approval prospects and commercial viability of ARC-520; and as a result, the Company's public statements were materially false and misleading at all relevant times.

On November 8, 2016, Arrowhead revealed that the U.S. Food & Drug Administration would be placing a clinical hold on the Company’s Heparc-2004 clinical study of ARC-520, likely due to deaths at the highest dose of an ongoing non-human primate toxicology study.

Following this news, NASDAQ: ARWR dropped 31.26% on November 9, 2016.

If you were negatively impacted by your investment in Arrowhead Pharmaceuticals Inc securities between May 11, 2015 and November 8, 2016 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation.

Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/

or

Facsimile: +1 (619) 785 – 3185

Transactions
Buy date (mm/dd/yyyy) Number of shares Price per share
Sell date (mm/dd/yyyy) Number of shares Price per share
Please wait...